Raymond James Financial
ONCY

Raymond James Financial’s Oncolytics Biotech ONCY Stock Holding History

Raymond James Financial’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.6K Buy
33,751
+383
+1% +$381 ﹤0.01% 5182
2025
Q4 		$29.2K Buy
+33,368
New +$36.1K ﹤0.01% 5057
2025
Q3 		– Sell
-6,450
Closed -$4.99K – 6186
2025
Q2 		$4.99K Buy
+6,450
New +$3.42K ﹤0.01% 6173

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Raymond James Financial's ONCY Position: Q1 2026 in Review

Raymond James Financial increased its Oncolytics Biotech (ONCY) stake by 1.1% in Q1 2026, buying an estimated $381 and bringing the position to 33,751 shares worth $28.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5182.

Raymond James Financial first reported a position in ONCY in Q2 2025 and has held it in 3 quarters since. The position peaked at $29.2K in Q4 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Raymond James Financial held 33,751 shares of Oncolytics Biotech worth $28.6K as of Q1 2026.
  • Raymond James Financial bought 383 Oncolytics Biotech shares in Q1 2026, an estimated $381.
  • Oncolytics Biotech made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5182 holding.
  • Raymond James Financial first reported a position in Oncolytics Biotech in Q2 2025 and has held it in 3 quarters since.
  • Raymond James Financial's Oncolytics Biotech position peaked at $29.2K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.